Abstract
Until recently, long-term regimens consisting of daily intravenous infusions of ganciclovir or foscarnet were the only available treatments for patients with cytomegalovirus (CMV) retinitis, a sight-threatening complication that affects approximately one third of patients in the United States with the acquired immunodeficiency syndrome (AIDS).1,2 In the past three years, the results of 11 randomized clinical trials of four new treatments for AIDS-related CMV retinitis have been reported.313 Thus, there are now new therapies from which clinicians can choose.Incidence and Natural History of CMV RetinitisCMV end-organ disease has emerged as one of the most common serious complications . . .

This publication has 71 references indexed in Scilit: